Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

es in treating resistant bacterial infections, particularly those caused by MRSA. With Phase 3 trial results showing efficacy in only 3 to 7 days of treatment, we believe oritavancin may become part of a new treatment paradigm for infections caused by MRSA and other gram-positive bacteria, and could confer pharmacoeconomic benefits, if approved."

"Despite the introduction of several new antibiotics in the past decade, we continue to see an increase in the development of resistant gram-positive bacteria," said Peter Appelbaum, M.D., Ph.D., professor, division of clinical pathology and medical director, clinical microbiology at Penn State University. "There is an ongoing need for new bactericidal antibiotics that address the limitations of currently marketed therapies. Oritavancin has proven to be very potent in vitro against a broad spectrum of gram-positive organisms resistant to other agents. Also, due to its multiple mechanisms of action, oritavancin may hinder the rapid development of resistance; concordantly, contemporary surveillance studies have shown that oritavancin retains potency against all gram-positive organisms tested. The infectious disease community looks forward to adding a therapy with the characteristics of oritavancin."

More Background on the Market for Novel Antibiotics

There is a growing need for novel antibiotics since bacteria can mutate quickly and often develop resistance to existing antibiotics. Hospital-acquired infections are particularly likely to be resistant to existing antibiotics, but resistance is also growing rapidly in community- acquired infections. As bacteria become more resistant to currently marketed antibiotics, an increasing prevalence of drug-resistant bacterial pathogens can lead to increased mortality rates, prolonged hospitalizations, and increased healthcare costs.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and c
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Rhythm announced today the results of a ... novel ghrelin agonist for the treatment of diabetic gastroparesis ... RM-131 significantly accelerates early gastric emptying and reduces upper ... diabetic gastroparesis. The findings were presented at the Digestive ... and recently published in Clinical Gastroenterology and ...
(Date:5/20/2013)... Researchers from the Southern University of Denmark have ... the acne causing P.acnes bacteria. Researchers believe found that when ... oxygen deprived location to seek shelter and grow. When an ... ability to live in the open joint areas, causing inflammation ... The best acne treatment ” explains why starting a normal ...
(Date:5/20/2013)... 2013 On 25-28 July, 2013, UPCP ... Paris - the beautiful city of lights. , According ... is revolutionizing the medical world. Understanding and integrating genetic ... hallmark of this transformation. Much of the present medical ... epidemiologic studies of large cohorts that do not take ...
(Date:5/20/2013)... 20, 2013 In Early 2013, ... of biotoxin related illnesses , announced his vision for ... to advance his protocol for treating Chronic Inflammatory Response ... third physician to achieve certification in the Shoemaker Protocol. ... to practice the Shoemaker Protocol in other parts of ...
Breaking Biology Technology:Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2
... EAST NORRITON, Pa., Sept. 14, 2011 Tengion, Inc. (NASDAQ: ... announced that Brian Davis, Vice President Finance and Chief Financial ... Life Sciences Conference on Monday, September 19, 2011, at 1:30 ... presentation can be accessed under "Calendar of Events" in the ...
... a new technique that uses a single UV laser pulse ... method that could help scientists study the mechanical forces at ... lasers are a commonly-used tool for cutting into tissue, but ... a time in a series of steps. If the initial ...
... N.C., Sept. 13, 2011 Microban recently conducted ... planktonic and biofilm growth on High Consistency Rubber ... manufacture of urinary catheters.  Urinary infections are a ... current technologies have had limited success in reducing ...
Cached Biology Technology:Tengion to Present at UBS Global Life Sciences Conference 2Microban Medical Silver Antimicrobial Technologies for HCR Silicone Achieve 5 Log Reductions in Bacteria Growth and Prevent Biofilm Formation 2
(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/17/2013)... day, insects provide the white noise of the South, but ... year, the Southern air hangs heavy from the humidity and ... more than 140 species of frogs, toads and salamanders, is ... the ponds and swamps are the auditorium for their symphonic ... and Monitoring Initiative, or ARMI, have front-row seats. ...
(Date:5/17/2013)... iCargo project (Intelligent Cargo in Efficient and Sustainable Global ... to an improvement in the efficiency of intermodal loading ... decision making. It comprises 29 European organisations with experience ... It has a budget totalling 17,000,000 and a duration ... working to specify and develop the semantic components and ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... Babies conceived during a period of famine are at ... new research published in the international journal Addiction. ... GGZ, and Erasmus University Rotterdam studied men and women ... of the Dutch hunger winter. Those whose mothers ...
... is available in German . , A ... researchers of the Robert Koch Institute (Berlin), the Max ... Suisse des Recherches Scientifiques (Ivory Coast) confirms the disease ... from humans to wild apes. The study also showed ...
... Learning and Memory at MIT report in the Jan. 24 ... to see, for the first time, the effect of blocking ... This revolutionary method allowed Susumu Tonegawa, Picower Professor of ... major memory-forming circuit in the brain affected learning and memory ...
Cached Biology News:Hungry mothers risk addiction in their adult children 2Great apes endangered by human viruses 2New MIT tool probes brain circuits 2
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
... developed with the drug discovery process in ... and performance, Safire is the ideal instrument ... and high throughput screening. Safire is a ... offers a range of high speed detection ...
... This depletion cocktail is tailored ... cells from suspensions of non-human ... are separated using the StemSep ... negative selection system, achieving a ...
...
Biology Products: